- Home
- LRHC vs KZIA Comparison
LRHC vs KZIA Comparison
Compare LRHC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRHC
- KZIA
- Stock Information
- Founded
- LRHC 2004
- KZIA 1994
- Country
- LRHC United States
- KZIA Australia
- Employees
- LRHC N/A
- KZIA N/A
- Industry
- LRHC
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- LRHC
- KZIA Health Care
- Exchange
- LRHC Nasdaq
- KZIA Nasdaq
- Market Cap
- LRHC 8.4M
- KZIA 9.0M
- IPO Year
- LRHC 2023
- KZIA 1999
- Fundamental
- Price
- LRHC N/A
- KZIA $7.12
- Analyst Decision
- LRHC
- KZIA Strong Buy
- Analyst Count
- LRHC 0
- KZIA 3
- Target Price
- LRHC N/A
- KZIA $16.00
- AVG Volume (30 Days)
- LRHC 24.4K
- KZIA 302.5K
- Earning Date
- LRHC 11-19-2025
- KZIA 11-14-2025
- Dividend Yield
- LRHC N/A
- KZIA N/A
- EPS Growth
- LRHC N/A
- KZIA N/A
- EPS
- LRHC N/A
- KZIA N/A
- Revenue
- LRHC $78,037,079.00
- KZIA $1,549,158.00
- Revenue This Year
- LRHC N/A
- KZIA N/A
- Revenue Next Year
- LRHC N/A
- KZIA $49.25
- P/E Ratio
- LRHC N/A
- KZIA N/A
- Revenue Growth
- LRHC 54.92
- KZIA 248983.08
- 52 Week Low
- LRHC $4.33
- KZIA $2.86
- 52 Week High
- LRHC $142.40
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- LRHC N/A
- KZIA 44.01
- Support Level
- LRHC N/A
- KZIA $6.20
- Resistance Level
- LRHC N/A
- KZIA $8.00
- Average True Range (ATR)
- LRHC 0.00
- KZIA 0.48
- MACD
- LRHC 0.00
- KZIA -0.03
- Stochastic Oscillator
- LRHC 0.00
- KZIA 49.73
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.